Medpace Reports Strong Q4 Results but Stock Drops on Book-to-Bill Disappointment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MEDP?
Source: seekingalpha
- Strong Financial Performance: Medpace Holdings (MEDP) reported Q4 2025 GAAP EPS of $4.67, beating expectations by $0.48, and revenue of $708.5 million, exceeding forecasts by $17.57 million, indicating robust financial health.
- Optimistic 2026 Outlook: The company projects 2026 revenue between $2.755 billion and $2.855 billion, with consensus at $2.81 billion, while diluted EPS is expected to range from $16.68 to $17.50, surpassing the consensus of $16.49, reflecting strong growth potential.
- Disappointing Book-to-Bill Ratio: Despite the strong financial results, the book-to-bill ratio came in at 1.04, below the expected 1.15, indicating slightly weaker demand, which may undermine investor confidence and contribute to the stock's decline.
- Cash Flow Changes: Medpace ended 2025 with cash and cash equivalents of $497 million, down from $669.4 million at the end of 2024, suggesting potential pressures on cash management that could impact future investment capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 416.040
Low
462.00
Averages
569.17
High
660.00
Current: 416.040
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ten Large-Cap Stocks with Worst Performance Last Week
- Astera Labs: Astera Labs (NASDAQ:ALAB) saw a significant decline of 23.74% this week after reporting fourth-quarter financial results that fell short of market expectations, raising investor concerns about its future profitability.
- Medpace Holdings: Medpace Holdings (NASDAQ:MEDP) experienced a slump of 20.69% this week, driven by disappointing fourth-quarter results and multiple analyst firms lowering their price targets, which intensified negative sentiment around the stock.
- Zillow Group: Zillow Group (NASDAQ:Z) decreased by 20.89% this week due to mixed fourth-quarter financial results that failed to boost investor confidence, leading to downward pressure on its stock price.
- AST SpaceMobile: AST SpaceMobile (NASDAQ:ASTS) fell 17.9% this week after announcing a $1 billion convertible senior notes offering, which was met with negative market reactions due to concerns over the implications of its financing plans.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment regarding these firms' prospects, which could influence investor decisions and market dynamics.
- Upgrades and Downgrades: While specific names of upgrades and downgrades are not detailed, such changes typically have a direct impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these shifts.
- Market Reaction Expectations: Adjustments in analyst ratings may trigger market volatility, especially when investor expectations are high for certain stocks, potentially leading to significant price fluctuations.
- Investor Decision Impact: Investors considering buying WMT stock should take into account the latest insights from analysts to make more informed investment decisions, even though specific analyst opinions were not elaborated in the report.
See More
U.S. Markets Closed Tuesday with Mixed Results as Spotify Technology Outperformed and Medpace Holdings Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. closed mixed on Tuesday, with the S&P 500 increasing by 0.10%.
- Decline in Other Indexes: The Dow Jones Industrial Average declined by 0.33%, while the Nasdaq Composite fell by 0.59%.
See More
Tenet Healthcare and AutoZone See Active Options Trading
- Tenet Healthcare Options Activity: Tenet Healthcare Corp. recorded an options trading volume of 5,517 contracts, equating to approximately 551,700 shares, which represents about 58.6% of its average daily trading volume of 940,865 shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: Notably, the $200 strike call option expiring on February 20, 2026, has seen 1,818 contracts traded today, representing around 181,800 underlying shares, suggesting that investors are increasingly optimistic about Tenet Healthcare's stock price appreciation.
- AutoZone Options Dynamics: AutoZone, Inc. has seen an options trading volume of 1,001 contracts, which translates to approximately 100,100 shares, accounting for 57.4% of its average daily trading volume of 174,495 shares over the past month, reflecting active market interest in its stock.
- High Strike Call Option Analysis: The $4000 strike call option expiring on February 20, 2026, has recorded a trading volume of 504 contracts today, representing about 50,400 underlying shares, indicating investor confidence in AutoZone's future growth potential.
See More
Medpace Holdings Reports Q4 2025 Earnings with Elevated Cancellations
- Significant Revenue Growth: Medpace reported Q4 2025 revenue of $708.5 million, a 32% year-over-year increase, with full-year revenue reaching $2.53 billion, reflecting a 20% growth from 2024, indicating strong market performance.
- Strong EBITDA Performance: The company achieved an EBITDA of $160.2 million in Q4, up 20% year-over-year, with full-year EBITDA at $557.7 million, although the EBITDA margin slightly decreased to 22.6%, demonstrating stable profitability.
- Cancellation Rate Risk: CEO Troendle highlighted that the cancellation rate in Q4 was the highest in over a year, resulting in a net book-to-bill ratio of 1.04, although management remains cautiously optimistic about future cancellation trends.
- Positive 2026 Outlook: Medpace expects total revenue for 2026 to range between $2.755 billion and $2.855 billion, representing growth of 8.9% to 12.8%, with EBITDA projected between $605 million and $635 million, reflecting confidence in future growth.
See More
Medpace Reports Strong Q4 Results but Stock Drops on Book-to-Bill Disappointment
- Strong Financial Performance: Medpace Holdings (MEDP) reported Q4 2025 GAAP EPS of $4.67, beating expectations by $0.48, and revenue of $708.5 million, exceeding forecasts by $17.57 million, indicating robust financial health.
- Optimistic 2026 Outlook: The company projects 2026 revenue between $2.755 billion and $2.855 billion, with consensus at $2.81 billion, while diluted EPS is expected to range from $16.68 to $17.50, surpassing the consensus of $16.49, reflecting strong growth potential.
- Disappointing Book-to-Bill Ratio: Despite the strong financial results, the book-to-bill ratio came in at 1.04, below the expected 1.15, indicating slightly weaker demand, which may undermine investor confidence and contribute to the stock's decline.
- Cash Flow Changes: Medpace ended 2025 with cash and cash equivalents of $497 million, down from $669.4 million at the end of 2024, suggesting potential pressures on cash management that could impact future investment capabilities.
See More
Ten Large-Cap Stocks with Worst Performance Last Week
- Astera Labs: Astera Labs (NASDAQ:ALAB) saw a significant decline of 23.74% this week after reporting fourth-quarter financial results that fell short of market expectations, raising investor concerns about its future profitability.
- Medpace Holdings: Medpace Holdings (NASDAQ:MEDP) experienced a slump of 20.69% this week, driven by disappointing fourth-quarter results and multiple analyst firms lowering their price targets, which intensified negative sentiment around the stock.
- Zillow Group: Zillow Group (NASDAQ:Z) decreased by 20.89% this week due to mixed fourth-quarter financial results that failed to boost investor confidence, leading to downward pressure on its stock price.
- AST SpaceMobile: AST SpaceMobile (NASDAQ:ASTS) fell 17.9% this week after announcing a $1 billion convertible senior notes offering, which was met with negative market reactions due to concerns over the implications of its financing plans.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment regarding these firms' prospects, which could influence investor decisions and market dynamics.
- Upgrades and Downgrades: While specific names of upgrades and downgrades are not detailed, such changes typically have a direct impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these shifts.
- Market Reaction Expectations: Adjustments in analyst ratings may trigger market volatility, especially when investor expectations are high for certain stocks, potentially leading to significant price fluctuations.
- Investor Decision Impact: Investors considering buying WMT stock should take into account the latest insights from analysts to make more informed investment decisions, even though specific analyst opinions were not elaborated in the report.
See More
U.S. Markets Closed Tuesday with Mixed Results as Spotify Technology Outperformed and Medpace Holdings Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. closed mixed on Tuesday, with the S&P 500 increasing by 0.10%.
- Decline in Other Indexes: The Dow Jones Industrial Average declined by 0.33%, while the Nasdaq Composite fell by 0.59%.
See More
Tenet Healthcare and AutoZone See Active Options Trading
- Tenet Healthcare Options Activity: Tenet Healthcare Corp. recorded an options trading volume of 5,517 contracts, equating to approximately 551,700 shares, which represents about 58.6% of its average daily trading volume of 940,865 shares over the past month, indicating heightened market interest in its future performance.
- High Strike Call Options: Notably, the $200 strike call option expiring on February 20, 2026, has seen 1,818 contracts traded today, representing around 181,800 underlying shares, suggesting that investors are increasingly optimistic about Tenet Healthcare's stock price appreciation.
- AutoZone Options Dynamics: AutoZone, Inc. has seen an options trading volume of 1,001 contracts, which translates to approximately 100,100 shares, accounting for 57.4% of its average daily trading volume of 174,495 shares over the past month, reflecting active market interest in its stock.
- High Strike Call Option Analysis: The $4000 strike call option expiring on February 20, 2026, has recorded a trading volume of 504 contracts today, representing about 50,400 underlying shares, indicating investor confidence in AutoZone's future growth potential.
See More
Medpace Holdings Reports Q4 2025 Earnings with Elevated Cancellations
- Significant Revenue Growth: Medpace reported Q4 2025 revenue of $708.5 million, a 32% year-over-year increase, with full-year revenue reaching $2.53 billion, reflecting a 20% growth from 2024, indicating strong market performance.
- Strong EBITDA Performance: The company achieved an EBITDA of $160.2 million in Q4, up 20% year-over-year, with full-year EBITDA at $557.7 million, although the EBITDA margin slightly decreased to 22.6%, demonstrating stable profitability.
- Cancellation Rate Risk: CEO Troendle highlighted that the cancellation rate in Q4 was the highest in over a year, resulting in a net book-to-bill ratio of 1.04, although management remains cautiously optimistic about future cancellation trends.
- Positive 2026 Outlook: Medpace expects total revenue for 2026 to range between $2.755 billion and $2.855 billion, representing growth of 8.9% to 12.8%, with EBITDA projected between $605 million and $635 million, reflecting confidence in future growth.
See More
Medpace Reports Strong Q4 Results but Stock Drops on Book-to-Bill Disappointment
- Strong Financial Performance: Medpace Holdings (MEDP) reported Q4 2025 GAAP EPS of $4.67, beating expectations by $0.48, and revenue of $708.5 million, exceeding forecasts by $17.57 million, indicating robust financial health.
- Optimistic 2026 Outlook: The company projects 2026 revenue between $2.755 billion and $2.855 billion, with consensus at $2.81 billion, while diluted EPS is expected to range from $16.68 to $17.50, surpassing the consensus of $16.49, reflecting strong growth potential.
- Disappointing Book-to-Bill Ratio: Despite the strong financial results, the book-to-bill ratio came in at 1.04, below the expected 1.15, indicating slightly weaker demand, which may undermine investor confidence and contribute to the stock's decline.
- Cash Flow Changes: Medpace ended 2025 with cash and cash equivalents of $497 million, down from $669.4 million at the end of 2024, suggesting potential pressures on cash management that could impact future investment capabilities.
See More
